CD8A and neoplasm: Using our recently identified short, H2Kd-restricted, tumor-specific neoantigen [34], we present the results of iterative in vivo adjuvant screening using CoPoP-neoantigen particles with integrated lipid adjuvants to identify adjuvants that can rapidly induce antigen-specific CD8+ T cell responses and which additional adjuvants can be added for further immunogenic synergy.